Category: Enzyvant

Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform designed to treat profound immunodeficiencies Left untreated, congenital athymia is uniformly fatal, with death typically occurring in first 24 months of life Company to present at Roivant Pipeline Day in New York City on June 6, 2019 CAMBRIDGE, Mass., and BASEL, Switzerland, June 5, 2019…

Enzyvant’s Investigational Regenerative Treatment for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting

CAMBRIDGE, Mass. and BASEL, April 3, 2019 /PRNewswire/ – Enzyvant today announced that its investigational regenerative treatment (RVT-802) in late-stage development for congenital athymia will be featured during a platform presentation, at a symposium, and in a poster session at the Clinical Immunology Society (CIS) 2019 annual meeting in Atlanta, GA, April 4-7. Congenital athymia…

Enzyvant’s Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

CAMBRIDGE, Mass. and BASEL, Switzerland, March 21, 2019 – Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Fast Track designations for RVT-801, an investigational enzyme replacement therapy. RVT-801 has previously been…

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

CAMBRIDGE, Massachusetts and BASEL, Switzerland, Feb. 21, 2019 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases, today announced the appointment of Rachelle Jacques as Chief Executive Officer. Ms. Jacques joins Enzyvant from Alexion where she most recently served as Senior Vice President and Global Franchise Head of Complement. Previously, Ms.…

Enzyvant to Highlight Investigational RVT-801 Program and Farber Disease Natural History Study at Upcoming WORLDSymposium™

BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 4, 2019 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases, today announced that abstracts highlighting the development of its investigational RVT-801 program and the natural history of Farber disease will be presented in Orlando, Florida, by Enzyvant and its collaborators at the 2019 WORLDSymposium™, an annual conference…

Enzyvant Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

BASEL, Switzerland, December 12, 2018 /PR Newswire/ – Enzyvant, a biopharmaceutical company focused on developing therapies for people with rare diseases, today announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston is a veteran biopharmaceutical executive with more than 25 years’ experience leading global business and financial…